<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04803734</url>
  </required_header>
  <id_info>
    <org_study_id>TW20-4502</org_study_id>
    <nct_id>NCT04803734</nct_id>
  </id_info>
  <brief_title>Bioequivalence Between Albuterol Sulfate Inhalation Aerosol 108mcg Per Actuation and Proair HFA (Albuterol Sulfate) Inhalation Aerosol 90 mcg Per Actuation in Healthy Volunteers Under Fasting Conditions</brief_title>
  <official_title>A Randomized, Single-dose, Open-label, Two-way Crossover Pivotal Study to Assess the Bioequivalence Between Albuterol Sulfate Inhalation Aerosol 108mcg Per Actuation (MDI, eq. to Albuterol 90mcg/Puff) and Proair HFA (Albuterol Sulfate) Inhalation Aerosol 90 mcg Per Actuation (MDI, eq. to Albuterol 90mcg/Puff) in Healthy Volunteers Under Fasting Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Intech Biopharm Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Intech Biopharm Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the bioequivalence between two formulations of&#xD;
      MDI, eq. to albuterol 90mcg/puff in healthy volunteers under fasting conditions.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 28, 2021</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Actual">May 10, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>0 hour (pre-dose), as well as at 2, 5, 10, 15, 20, 30, 45 minutes, and 1, 1.25, 1.5, 1.75, 2, 2.25, 2.5, 3, 4, 6, 8, 12, 16 and 24 hours post-dose</time_frame>
    <description>Pharmacokinetics of Albuterol Sulfate by Assessment of Observed Maximum Plasma Concentration (Cmax)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-t)</measure>
    <time_frame>0 hour (pre-dose), as well as at 2, 5, 10, 15, 20, 30, 45 minutes, and 1, 1.25, 1.5, 1.75, 2, 2.25, 2.5, 3, 4, 6, 8, 12, 16 and 24 hours post-dose</time_frame>
    <description>Pharmacokinetics of Albuterol Sulfate by Assessment of Observed Maximum Plasma Concentration (AUC(0-t))</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-inf)</measure>
    <time_frame>0 hour (pre-dose), as well as at 2, 5, 10, 15, 20, 30, 45 minutes, and 1, 1.25, 1.5, 1.75, 2, 2.25, 2.5, 3, 4, 6, 8, 12, 16 and 24 hours post-dose</time_frame>
    <description>Pharmacokinetics of Albuterol Sulfate by Assessment of Observed Maximum Plasma Concentration (AUC(0-inf))</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>0-24 hours</time_frame>
    <description>Other Pharmacokinetics of Albuterol Sulfate by Assessment of Time to Maximum Plasma Concentration (Tmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T1/2</measure>
    <time_frame>0-24 hours</time_frame>
    <description>Other Pharmacokinetics of Albuterol Sulfate by Assessment of Terminal Elimination Half-life (T1/2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>kel(λ)</measure>
    <time_frame>0-24 hours</time_frame>
    <description>Other Pharmacokinetics of Albuterol Sulfate by Assessment of Terminal Climination Rate Constant (kel(λ))</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRT</measure>
    <time_frame>0-24 hours</time_frame>
    <description>Other Pharmacokinetics of Albuterol Sulfate by Assessment of Mean residence time (MRT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Through study completion, an average of 16 days</time_frame>
    <description>The number and type of adverse events will be reported from Day 1 of period 1 through Day 2 of period 2 including a 14 day washout period between periods (total time is approximately 16 days)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Test</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Albuterol Sulfate inhalation aerosol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reference</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Proair HFA (albuterol sulfate) Inhalation Aerosol</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Albuterol Sulfate inhalation aerosol 108mcg per actuation</intervention_name>
    <description>MDI, 2 puffs, single dose, fasting</description>
    <arm_group_label>Test</arm_group_label>
    <other_name>Albuterol 90mcg/puff</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Proair HFA (albuterol sulfate) Inhalation Aerosol 90 mcg per actuation</intervention_name>
    <description>MDI, 2 puffs, single dose, fasting</description>
    <arm_group_label>Reference</arm_group_label>
    <other_name>Albuterol 90mcg/puff</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy male and female volunteers, aged 20-60, inclusive.&#xD;
&#xD;
          2. BMI of 18.0-30.0 kg/m², inclusive. The body weight should be over 50 kg, inclusive.&#xD;
             (BMI will be calculated as weight in kilogram [kg]/height in meters² [m²]).&#xD;
&#xD;
          3. Healthy or Non Clinical Significant, according to the medical history, ECG, chest&#xD;
             X-ray and physical examination as determined by the Principal&#xD;
             Investigator/Sub-Investigator.&#xD;
&#xD;
          4. Systolic blood pressure between 90-139 mmHg, inclusive, and diastolic blood pressure&#xD;
             between 50-90 mmHg, inclusive, and pulse rate between 50-100 bpm, inclusive and&#xD;
             temperature between 35.0-37.4℃.&#xD;
&#xD;
          5. Screening laboratory values within reference range or NCS as determined by the&#xD;
             Principal Investigator/Sub-Investigator.&#xD;
&#xD;
          6. Ability to comprehend and be informed of the nature of the study, as assessed by&#xD;
             clinical staff. Capable of giving written informed consent prior to receiving any&#xD;
             study medication. Must be able to communicate effectively with clinical staff.&#xD;
&#xD;
          7. Willing to fast for at least 14 hours and to consume standard meals.&#xD;
&#xD;
          8. Availability to volunteer for the entire study duration and willing to adhere to all&#xD;
             protocol requirements.&#xD;
&#xD;
          9. Agree not to have a tattoo, body piercing, or other any invasive procedure and blood&#xD;
             donation until the end of the study.&#xD;
&#xD;
         10. Never-smokers; or former smokers who have smoked ≥ 100 cigarettes in their lifetime&#xD;
             and have not consumed any tobacco or tobacco containing products for at least 12&#xD;
             months prior to screening.&#xD;
&#xD;
         11. Subjects who are non-asthmatic, defined as no clinical history of asthma, allergy or&#xD;
             atopy.&#xD;
&#xD;
         12. Able to perform special breathing using nebulizer correctly as per the required&#xD;
             standard.&#xD;
&#xD;
         13. Subjects must fulfill at least one of the following:&#xD;
&#xD;
               -  Be surgically sterile for a minimum of 6 months;&#xD;
&#xD;
               -  Post-menopausal for a minimum of 1 year;&#xD;
&#xD;
               -  Agree to avoid pregnancy and use medically acceptable method of contraception&#xD;
                  from screening day until 30 days after the study ends (last study procedure).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Known history or presence of any clinically significant hepatic (e.g. active liver&#xD;
             disease, hepatic impairment), renal/genitourinary (e.g. renal impairment),&#xD;
             gastrointestinal, cardiovascular, cerebrovascular, pulmonary, endocrine (e.g.&#xD;
             hypothyroidism), immunological, musculoskeletal (e.g. myopathy, rhabdomyolysis),&#xD;
             neurological, psychiatric, dermatological, hematological disease, or any other medical&#xD;
             conditions, unless determined as not clinically significant by the Principal&#xD;
             Investigator/Sub-Investigator.&#xD;
&#xD;
          2. Presence of any clinically significant illness within 30 days prior to first dosing,&#xD;
             as determined by the Principal Investigator/Sub-Investigator.&#xD;
&#xD;
          3. Presence of any significant physical or organ abnormality as determined by the&#xD;
             Principal Investigator/Sub-Investigator.&#xD;
&#xD;
          4. A positive test result for any of the following: HIV, Hepatitis B surface antigen,&#xD;
             Hepatitis C, drugs of abuse (amphetamines, barbiturates, benzodiazepines, cocaine,&#xD;
             opiates, phencyclidine, tetrahydrocannabinol), breath alcohol test. Positive pregnancy&#xD;
             test for female subjects.&#xD;
&#xD;
          5. Known history or presence of:&#xD;
&#xD;
               -  Alcohol abuse within one year prior to first drug administration;&#xD;
&#xD;
               -  Drug abuse or dependence;&#xD;
&#xD;
               -  Hypersensitivity or idiosyncratic reaction to albuterol, its excipients, and/or&#xD;
                  related substances;&#xD;
&#xD;
               -  Allergy to standardized meal provided by site and/or presence of any dietary&#xD;
                  restrictions;&#xD;
&#xD;
          6. Intolerance to and/or difficulty in blood sampling through venipuncture.&#xD;
&#xD;
          7. Abnormal diet patterns (for any reason) during the 4 weeks preceding the study,&#xD;
             including fasting, high protein diets etc.&#xD;
&#xD;
          8. Except for screening procedures, blood donation that results in blood loss of not more&#xD;
             than 250 ml in the past 2 months prior to first dosing; blood loss of more than 250 ml&#xD;
             within 3 months prior to first dosing.&#xD;
&#xD;
          9. Donation of plasma by plasmapheresis within 7 days prior to first drug administration.&#xD;
&#xD;
         10. Individuals who receives an investigational drug from 2 months prior to first drug&#xD;
             administration.&#xD;
&#xD;
         11. Consumption of products containing caffeine/methylxanthines, poppy seeds and/or&#xD;
             alcohol within 48 hours before dosing and products containing grapefruit and/or pomelo&#xD;
             (shown to inhibit cytochrome P450 [CYP] 3A4 activity) within 10 days prior to first&#xD;
             drug administration.&#xD;
&#xD;
         12. Use of any medication, including oral multivitamins, herbal and/or dietary supplements&#xD;
             within 30 days prior to first drug administration (except topical agents without&#xD;
             systemic absorption as determined by the Principal Investigator/Sub-Investigator).&#xD;
&#xD;
         13. Females taking oral or transdermal hormonal contraceptives within 30 days prior to&#xD;
             first drug administration.&#xD;
&#xD;
         14. Females having used implanted, injected, intravaginal, or intrauterine hormonal&#xD;
             contraceptive within 6 months prior to first drug administration.&#xD;
&#xD;
         15. Individuals having undergone any major surgery within 6 months prior to the start of&#xD;
             the study, unless deemed otherwise by Principal Investigator/Sub-Investigator.&#xD;
&#xD;
         16. Using tobacco products, nicotine products (patches, gum etc.) within 6 months prior to&#xD;
             first drug administration.&#xD;
&#xD;
         17. Lactating women.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Clinical Pharmacology Unit,Mackay Memorial Hospital</name>
      <address>
        <city>New Taipei City</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>March 11, 2021</study_first_submitted>
  <study_first_submitted_qc>March 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 18, 2021</study_first_posted>
  <last_update_submitted>May 28, 2021</last_update_submitted>
  <last_update_submitted_qc>May 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Aspiration</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Albuterol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

